GLP-1 therapy - twenty30 health

USPTF on Kids with Obesity; GLP-1s on Brain Diseases; Financial Incentives to Lose Weight; Novel Amylin Drug Drives 8.6% Weight Loss at 16 Weeks

June 23, 2024 No Comments

AT A GLANCE The US Preventive Services Task Force published in JAMA a Recommendation Statement on Interventions for High Body Mass Index in Children and Adolescents. Simar Bajaj at NewScientist on GLP-1s’ unexpected effects on the brain, to treat depression, anxiety, addiction and Alzheimer’s. JAMA Pediatrics publishes the impact of financial incentives on improved outcomes of a dietary intervention among 126 adolescents with severe obesity. Zealand Pharma drug petrelintide, which targets the

MASH Clash for Liver Disease; Google’s Verily Pivots to GLP-1 Meds; JPMorgan Chase $500M Bet on Weight-Loss Meds; MIT’s Bob Langer Launches NewCo; 40% Increase in Type 2 Diabetes in Young People

June 16, 2024 No Comments

AT A GLANCE STAT on Google’s health tech spinout Verily pivoting to offer GLP-1 drug prescriptions. MIT biotech legend Bob Langer and colleague Giovanni Traverso launched Syntis Bio, with a technology to coat the stomach, that impacts obesity. From Yahoo! Finance, JPMorgan Chase & Co.’s asset-management arm raised a $500 million fund to invest in weight-loss drugs. From Reuters, roughly one-third of US employer health plans are covering

Oral GLP-1 Charge; Weight Loss Drugs and Cancer; The Obese Police; Medicaid Coverage for Comprehensive Obesity Care.

June 9, 2024 No Comments

AT A GLANCE Structure Therapeutics announced weight loss of 6.2% at 12 weeks in 37 subjects on GSBR-1290 – a once-daily oral GLP-1 drug. UK-based The Guardian newspaper reports ‘…Weight-loss drugs offer a new weapon in the global fight against cancer…’ STAT notes Eli Lilly’s Zepbound obesity drug ‘…improved living scarring in a mid-stage study of the liver disease MASH.’ Tamar Haspel at The Atlantic refers to new guidelines

Nestle Frozen Foods for GLP-1 Users; Weight-Loss Drug Sales in 2033 Balloon to $150B; No Staying Power Beyond 12 Weeks; Black Americans are Left Out.

June 2, 2024 No Comments

AT A GLANCE CNN on Nestle ‘…releasing a lineup of frozen food for people on Ozempic and other GLP-1 drugs.’ Deena Beasley at Reuters reports BMO Capital Markets now estimates annual weight-loss drug sales reaching $150 billion by 2033. South Park; The End of Obesity is very good satire, and eerily realistic. Anissa Durham on STAT ‘…New obesity drugs are seemingly everywhere. Black Americans feel left out.’

24% Reduction in Kidney Events on Semaglutide; TikTok bans Weight Meds Marketing; Bariatric Surgery Cures Infertility; 50% Discontinue GLP-1s at 1y.

May 26, 2024 No Comments

AT A GLANCE The American Heart Association ‘…highlights the barriers to treatment and improvements needed in translating the science of obesity to patient care.’ Daniel Gilbert at The Washington Post reports on the ban of TikTok star Taylor Huber who is paid to promote weight-loss medications. The New England Journal of Medicine reports a 24% reduction in kidney disease events, or death from kidney-related or cardiovascular

Novo’s new Drug Development Partnership; Oprah on Making the Shift; No One Knows How to Talk About Weight Loss Anymore; One in Eight Adults in US have taken a GLP-1 Drug.

May 12, 2024 No Comments

AT A GLANCE Reuters states Novo Nordisk ties up with Metaphore from Flagship Pioneering to develop new obesity drugs. Oprah, in collaboration with Weightwatchers CEO Sima Sistani, joined by actress Rebel Wilson, as well as obesity experts this week. I am encouraged to read Jamie Ducharme’s article in TIME this week titled No One Knows How to Talk About Weight Loss Anymore – spot on! Betsy McKay

Just the Beginning for GLP-1 Costs; Pricing, Rebates and Access to GLP-1 Meds; No Increase in Surgical Complications for those on GLP-1s.

April 28, 2024 No Comments

AT A GLANCE Elaine Chen at STAT on new studies to suggest GLP-1 health care costs have only begun to climb. Large employers are trying to limit the costs of the expensive new generation of weight-loss drugs, from POLITICO. Delayed gastric emptying and pulmonary aspiration following induction of anesthesia in patients using GLP-1 drugs is not an issue, as per JAMA. The Kaiser Family Foundation analyzed Medicare

Novo’s Semaglutide for Heart Failure; Biocon Leads India’s Generic GLP-1 Charge; I’m a Doctor on Ozempic; Cost-Effectiveness of Semaglutide Versus Endoscopic Sleeve

April 14, 2024 No Comments

AT A GLANCE Biocon Ltd. is leading India’s push to weight loss medications as patents lapse, unleashing generic supply for the global weight-loss market, from Bloomberg. STAT News reports European regulators ‘…have found no evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.’ ‘I’m a doctor on Ozempic – it’s effective under one condition…’ says President and CEO of Philadelphia College of Osteopathic Medicine,

Costco’s Weight Loss Program; China Develops GLP-1 Drug; Not Everyone Loses Weight on Ozempic; Weed for Weight Loss; GLP-1 For Parkinson’s

April 7, 2024 No Comments

AT A GLANCE USA Today reports ‘…Costco and its low-cost health care partner are expanding into weight-loss management…’ Reuters notes a biosimilar version of Novo Nordisk’s popular diabetes drug Ozempic has been developed in China Sumathi Reddy at The Wall Street Journal writes some people don’t lose much weight on drugs like Ozempic. Dr. Amir Ghaferi and colleagues from Wisconsin review Metabolic Surgery for Diabetes Management

Wegovy for Medicare Beneficiaries; Bariatric Surgery Restrictions Eased by GLP-1 Costs; $6B Spend on GLP-1s by Medicare in 2022; $5 Per Month to Manufacture Ozempic; Viking Therapeutics Stock Charges

March 31, 2024 No Comments

AT A GLANCE San Diego biotech Viking Therapeutics shares were up 20% on news that the oral version of dual GLP-1/GIP drug VK2735 had succeeded its phase 1 trial. Peter Loftus at The Wall Street Journal reports CVS Health, Elevance Health and Kaiser Permanente would cover Wegovy for Medicare beneficiaries. Miriam E. Tucker at Medscape suggests ‘GLP-1 Costs May Ease Restrictions to Bariatric Surgery.’ The Kaiser Family Foundation analyzed Medicare

Category: GLP-1 therapy